Efficacy and Safety Profile of Exenatide Once Weekly Compared With Insulin Once Daily in Japanese Patients With Type 2 Diabetes Treated With Oral Antidiabetes Drug(s): Results From a 26-Week, Randomized, Open-Label, Parallel-Group, Multicenter, Noninferiority Study

Clinical Therapeutics

Volumn 34, Issue 9, 2012, Pages

  Inagaki, Nobuya ^a   Atsumi, Yoshihito ^b   Oura, Tomonori ^c   Saito, Hitoshi ^c   Imaoka, Takeshi ^c  

^a KYOTO UNIVERSITY   (Japan)

^b SAISEIKAI CENTRAL HOSPITAL   (Japan)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

Diabetes mellitus; Exenatide; GLP 1 receptor agonist; Insulin glargine; Japanese; Once weekly; Type 2

Indexed keywords

BIGUANIDE; EXENDIN 4; GLUCOSE; HEMOGLOBIN A1C; INSULIN GLARGINE; THIAZOLIDINE DERIVATIVE;

ABDOMINAL DISCOMFORT; ACUTE CHOLECYSTITIS; ADULT; ARTICLE; ASTHMATIC STATE; BACKACHE; BODY WEIGHT; CONSTIPATION; CONTACT DERMATITIS; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART FAILURE; HEMOGLOBIN DETERMINATION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INJECTION SITE INDURATION; INJECTION SITE PRURITUS; INSULIN DEPENDENT DIABETES MELLITUS; INTESTINE DIVERTICULOSIS; JAPANESE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSTRUCTIVE JAUNDICE; PANCYTOPENIA; PROLIFERATIVE RETINOPATHY; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; VITAL SIGN; VOMITING; WEIGHT REDUCTION;

EID: 84866144740     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2012.07.007     Document Type: Article

References (41)

1. Madsbad S., Kielgast U., Asmar M., et al. An overview of once-weekly GLP-1 receptor agonists-available efficacy and safety data and perspectives for the future. Diabetes Obes Metab 2011, 13:394-407.
2. Gerich J. DPP-4 inhibitors: what may be the clinical differentiators?. Diabetes Res Clin Pract 2010, 90:131-140.
3. Scott L.J. Alogliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs 2010, 70:2051-2072.
4. Neumiller J.J. Clinical pharmacology of incretin therapies for type 2 diabetes mellitus: implications for treatment. Clin Ther 2011, 33:528-576.
5. Parkes D.G., Pittner R., Jodka C., et al. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro. Metabolism 2001, 50:583-589.
6. Egan J.M., Clocquet A.R., Elahi D. The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes. J Clin Endocrinol Metab 2002, 87:1282-1290.
7. Degn K.B., Brock B., Juhl C.B., et al. Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia. Diabetes 2004, 53:2397-2403.
8. Kolterman O.G., Buse J.B., Fineman M.S., et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003, 88:3082-3089.
9. Kolterman O.G., Kim D.D., Shen L., et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm 2005, 62:173-181.
10. Edwards C.M., Stanley S.A., Davis R., et al. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab 2001, 281:E155-E161.
11. Heine R.J., Van Gaal L.F., Johns D., et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005, 143:559-569.
12. Barnett A.H., Burger J., Johns D., et al. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin Ther 2007, 29:2333-2348.
13. Bunck M.C., Diamant M., Corner A., et al. One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care 2009, 32:762-768.
14. Davies M.J., Donnelly R., Barnett A.H., et al. Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study. Diabetes Obes Metab 2009, 11:1153-1162.
15. Kadowaki T., Namba M., Imaoka T., et al. Improved glycemic control and reduced bodyweight with exenatide: a double-blind, randomized, Phase 3 study in Japanese patients with suboptimally controlled type 2 diabetes over 24 weeks. J Diabetes Invest 2011, 2:210-217.
16. Inagaki N., Ueki K., Yamamura A., et al. Long-term safety and efficacy of exenatide twice daily in Japanese patients with suboptimally controlled type 2 diabetes. J Diabetes Invest 2011, 2:448-456.
17. Drucker D.J., Buse J.B., Taylor K., et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008, 372:1240-1250.
18. Blevins T., Pullman J., Malloy J., et al. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab 2011, 96:1301-1310.
19. Treatment Guide for Diabetes 2012, Japan Diabetes Society, Bunkodo, Tokyo, Japan, In Japanese.
20. Peyrot M., Rubin R.R., Lauritzen T., et al. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 2005, 28:2673-2679.
21. Skovlund E., Peyrot M. The Diabetes Attitudes, Wishes, and Needs (DAWN) Program: a new approach to improving outcomes of diabetes care. Diabetes Spectrum 2005, 18:136-142.
22. Phillips P. Type 2 diabetes-failure, blame and guilt in the adoption of insulin therapy. Rev Diabet Stud 2005, 2:35-39.
23. Kim D., MacConell L., Zhuang D., et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 2007, 30:1487-1493.
24. Diamant M., Van Gaal L., Stranks S., et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet 2010, 375:2234-2243.
25. Iwamoto K., Nasu R., Yamamura A., et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of exenatide once weekly in Japanese patients with type 2 diabetes. Endocr J 2009, 56:951-962.
26. Rosenstock J., Dailey G., Massi-Benedetti M., et al. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care 2005, 28:950-955.
27. Schreiber S.A. Insulin glargine in type 2 diabetes in everyday clinical practice: 7 years experience. Diabetes Obes Metab 2008, 10(SUPPL 2):24-34.
28. Declaration of Helsinki, 59th WMA General Assembly, Seoul, October 2008 World Medical Association, Accessed April 23, 2012. http://www.wma.net/en/30publications/10policies/b3/17c.pdf.
29. Ministry of Health, Labor and Welfare Ministerial Ordinance, No. 24; dated February 29, 2008 Ministry of Health, Labor and Welfare Good Clinical Practice, Accessed August 6, 2012. http://www.pmda.go.jp/english/service/pdf/ministerial/20110307No_28.pdf.
30. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus 1999, World Health Organization, World Health Organization, Geneva, Switzerland, Accessed April 23, 2012. http://whqlibdoc.who.int/hq/1999/who_ncd_ncs_99.2.pdf.
31. Fineman M.S., Bicsak T.A., Shen L.Z., et al. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 2003, 26:2370-2377.
32. Armitage P., Berg G., Matthews J.N.S. Statistical Methods in Medical Research 2002, Blackwell Science, Oxford, UK. 4th ed.
33. Fineman M.S., Mace K.F., Diamant M., et al. Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment. Diabetes Obes Metab 2012, 14:546-554.
34. Buse J.B., Henry R.R., Han J., et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004, 27:2628-2635.
35. DeFronzo R.A., Ratner R.E., Han J., et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005, 28:1092-1100.
36. Kendall D.M., Riddle M.C., Rosenstock J., et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005, 28:1083-1091.
37. Nauck M.A., Duran S., Kim D., et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 2007, 50:259-267.
38. Kadowaki T., Namba M., Yamamura A., et al. Exenatide exhibits dose-dependent effects on glycemic control over 12 weeks in Japanese patients with suboptimally controlled type 2 diabetes. Endocr J 2009, 56:415-424.
39. Zinman B., Hoogwerf B.J., Duran Garcia S., et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2007, 146:477-485.
40. Fineman M.S., Shen L.Z., Taylor K., et al. Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes. Diabetes Metab Res Rev 2004, 20:411-417.
41. Mikhail N. Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes. Expert Opin Investig Drugs 2008, 17:845-853.